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Present status and future direction of clinical trials in 
advanced endometrial carcinoma
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Endometrial adenocarcinoma is staged surgically, and advanced endometrial carcinoma is considered to be FIGO stage 
III and IV. The Gynecologic Oncology Group (GOG) has come a long way in developing new strategies in the 
management of advanced endometrial carcinoma. Combining surgery, radiation, and chemotherapy, the 5-year 
survival has improved to between 40-60% in newly diagnosed advanced endometrial carcinoma. Recent findings in 
GOG184 indicate that multiple risk factors noted at the time of surgical staging could lead to concurrent clinical trials 
that could be completed expeditiously rather than a subsequent ten year long phase III trial including all the various 
risk subgroups of patients. This review is a focus on the accomplishments of the GOG in advanced endometrial 
carcinoma with an emphasis on future challenges. 
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INTRODUCTION
 Endometrial adenocarcinoma is staged surgically, and 
advanced endometrial carcinoma is considered to be FIGO 
Stage III and FIGO Stage IV. Stage III patients include those 
with tumor invading the adnexa, uterine serosa, or pelvic 
and/or para-aortic nodes, as well as malignancy found in 
pelvic washings or upper vagina. Low risk endometrial 
carcinoma (FIGO Stage I) has high acceptable cure rates by 
surgery alone except in higher risk (FIGO Stage IC, II and early 
III) patients. Adjunctive trials are currently underway to 
establish the role of radiation and chemotherapy in such 
higher risk patients.
  By taking advantage of discoveries made in treatment of 
recurrence after prior therapy, advances have been made by 
the Gynecologic Oncology Group (GOG) in treatment of 
advanced endometrial carcinoma. Combining surgery, radia-
tion and chemotherapy, the five year survival has improved to 
between 40-60% in newly diagnosed advanced endometrial 
carcinoma. Yet, recent findings in GOG184 indicate that 
multiple risk factors noted at the time of surgical staging 
could lead to concurrent clinical trials that could be completed 
expeditiously rather than a subsequent ten year long phase III 
trial including all the various risk subgroups of patients.1 
  This review is a focus on the accomplishments of the 
Gynecologic Oncology Group (GOG) in advanced endo-
metrial carcinoma with an emphasis on future challenges. Is it 
time for a different clinical trial approach? 
CHEMOTHERAPY
  The GOG (www.gog.org) over the past twenty years has 
performed prospective phase II and phase III clinical trials to 
identify more active regimens for advanced endometrial 
carcinoma treatment. Undoubtedly, progress has been made 
with use of radiation in combination with new, more effective 
chemotherapy.
  Doxorubicin was the first highly active drug for endometrial 
carcinoma to be identified in the 1970's, but it has taken 
twenty years to conduct clinical trials in advanced endo-
metrial carcinoma to assess the impact of other chemo-
therapy. Initially, these clinical trials were slow-going because 
of the reluctance to treat recurrent patients primarily with 
chemotherapy rather than progestin therapy. Comprehensive 
testing of potential chemotherapeutic agents has since been 
evaluated in both first and second line settings (Table 1, 2). 
  Recommendations for primary chemotherapy treatment 
changed when survival of patients with grade 1 lesions treated 
with progestin therapy was no higher than 5-10%, despite an 
approximate 25% overall response (Table 3).
  For example, in GOG 153, the alternating dose of megestrol 
acetate and tamoxifen achieved a response rate of 27% and 
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Table 1. Second line GOG phase II trials in endometrial carcinoma
Year Drug Response CR PR    Response rate
1984
1994
1995
1996
1998
1998
1999
2005
2006
2008
Cisplatin
Etoposide
Paclitaxel
Actinomycin
Lip doxorubicin
Pyrazoloaridin
Topotecan
Docetaxel
Pemetrexed
Ixabepilone
  1/25
  0/22
12/44
  3/25
  4/42
  1/23
  2/22
  1/27
  1/26
  6/50
0
0
3
1
0
0
1
0

1        
1 
0
9
 2
4
1
1
1
1
5
  4%
  0%
28%
12%
10%
  4%
  9%
  4%
3.8%
12%
Table 2. First line GOG chemotherapy of advanced endometrial car-
cinoma
Year Agent Response CR PR Response rate
1986
1987
1989
1989
1993
1994
2004
Hexamethylmelamine
Methotrexate
Vincristine
Cisplatin
Paclitaxel
Ifosfamide
Liposomal. Doxorubicin
  2/25
  2/33
  6/33
10/50
10/28
  9/34
  6/52
0
1
1
2
4
2
2
2
1
5
8
6
7
4
   8%
   6%
  18%
  20%
  35%
  26%
11.5%
Table 3. First line GOG trials of advanced endometrial carcinoma 
with progestins
Year/
Protocol
Agents (patients)
Response 
rate 
Progression
free interval
(months)
Survival
months
1985
GOG48
1989
GOG81
1992
GOG121
1996
GOG 119
2000
GOG153
MPA (295)
[Medroxyprogesterone
 Acetate]
MPA200 mg (145)
MPA1000 mg (154)
Megestrol (Meg)
QD Tamoxifen G
Interm. Meg. (60) 
Megestrol×3
Tamoxifen×3 (61)
17%
25%
15%
26%
33%
6 CR
27%
12 CR
4.1
3.2
2.5
2.6
3
2.7
10.4
11.1
 7.0
 7.6
13
14
had the highest number of complete responders. Since the 
response rate was lower than that achieved by chemotherapy, 
hormonal therapy has been abandoned for GOG trials in 
advanced endometrial carcinoma. Exceptions for possible use 
of hormonal therapy in GOG trials are in purported 
endometrial complex hyperplasia with atypia or evaluation of 
new agents such as FaslodexR in GOG188. 
  A response rate of 30-40% can be expected with first line 
treatment using doxorubicin, but the survival remains low. 
Even so, first line testing of chemotherapy agents remains 
acceptable to best assess activity of new agents where survival 
remains low even with current three drug combination 
therapy. 
  First line GOG testing has led to subsequent trials using 
drug combinations that have achieved improved results. In 
addition, first line testing has avoided use of drugs such as 
liposomal doxorubicin which would appear as an ideal agent 
with markedly reduced toxicity. Yet, in both first and second 
line trials, liposomal doxorubicin had low activity in the range 
of 10-12% for recurrent endometrial carcinoma.
RADIATION AND CHEMOTHERAPY
  In the 1990's, the GOG began to explore the utility of whole 
abdominal radiation combined with chemotherapy for 
advanced endometrial carcinoma2-4 (Table 4). GOG 094 was 
successful in establishing the role of whole abdominal 
radiation especially for the high risk types of clear cell and 
papillary serous carcinoma.5 Concurrently, in GOG 107 the 
combination of cisplatin and doxorubicin in a phase III trial 
was proven superior to doxorubicin alone in recurrent 
endometrial carcinoma.6 In 1996, GOG 129C results indi-
cated that paclitaxel was highly active as second line treat-
ment in advanced endometrial carcinoma with a 28% overall 
response rate.7 By the year 2000, in GOG 122 chemotherapy 
alone was noted to be superior to whole abdominal radiation.8 
Shortly thereafter, the three drug combination of doxorubi-
cin, cisplatin and paclitaxel was noted to be superior to 
doxorubicin and cisplatin.9
  The GOG Final Statistical Report in January 2007 (www.gog. 
org) for GOG184 indicated that the addition of paclitaxel to 
doxorubicin and cisplatin following surgery and volume 
directed radiation did not increase survival. There has been no 
replacement yet activated for GOG184 largely because the 
control chemotherapy arm is unclear, and the question of how 
radiation and chemotherapy should be combined remains 
unanswered. In GOG 209, the current phase III protocol for 
recurrence, the combination of doxorubicin, cisplatin and 
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Table 4. GOG trials in advanced endometrial carcinoma
GOG 094: Whole abdomen radiation (WAI) tolerable in endometrial carcinoma (1995)
GOG 107: Cisplatin (Cis)+doxorubicin higher response than doxorubicin alone (1988-1992)
GOG 129C: Paclitaxel (Pac) phase II 28% response (1997)
GOG 122: Cisplatin+doxorubicin (Doxo) superior to WAI (1992-2002)
GOG 177: Cis/Doxo/Pac superior to Cis/Doxo in advanced endometrial carcinoma (1998-2002)
GOG 184: Surgery+radiation followed by doxorubicin and cisplatin w/without paclitaxel (2000-2004)
GOG 209: Doxorubicin, cisplatin and paclitaxel vs carboplatin and paclitaxel (2000 to Present)
paclitaxel (control arm) is being compared to carboplatin and 
paclitaxel. If the GOG 209 arms are similar, then the GOG 184 
replacement would likely be carboplatin and paclitaxel vs 
radiation. 
  Since the year 2000, in advanced endometrial carcinoma, the 
GOG has conducted phase II trials with several molecular 
targeting agents including imatinib (Gleevec), trastuzumab 
(Herceptin), and gefitinib (Iressa) as single agents with 
negligible evidence of activity. The GOG does have active 
trials of chemotherapy with a molecular targeting agent such 
as bevacizumab (Avastin) in GOG 218, but there are no 
randomized molecular targeting agent trials in advanced 
endometrial carcinoma.
CHALLENGES DERIVED FROM GOG184 
FOR FUTURE CONSIDERATION?
  Since GOG184 is the most recently concluded GOG clinical 
trial in advanced endometrial carcinoma, specific challenges 
for the future can be based on the findings of this trial.1 
  The GOG Corpus Committee is charged with the respon-
sibility of protocol development for advanced endometrial 
carcinoma. The statistical updates contained in the six month 
statistical reports, now readily available on the GOG web site, 
are reviewed at each six month meeting. The statistical 
abstracts of the study chairs that summarize the analyses of 
completed clinical trials are regularly reviewed by the 
committee members who also attend the presentation of the 
analyses. All of this information is used to craft a replacement 
protocol by the Corpus Committee which then requires 
approval by the GOG committee in charge of development of 
all GOG protocols. There must be final approval for activation 
by the National Cancer Institute.  
Unfortunately the timeline for the last phase III protocol for 
advanced endometrial carcinoma (GOG 184) took 10 years.
  �GDevelopment                               1 Year (1999-2000)
  �GEnrollment                              4 Years (2000-2004)
  �GFollow-Up  (62% Survival)               3 Years (2004-2007)
  �GAnalysis                                              1 Year (2007-2008)
  �GPresentation of Abstract of Trial Findings      1 Year (2008)
  �GFinal Publication                                                    2009?
  The ultimate goal in managing a large phase III trial of 
several hundred patients would be to have instant replace-
ments activated as soon as the prior study closes for patient 
entry. The minimal desirable goal would be to have as short a 
development phase as possible. Unfortunately, there is no 
GOG184 Replacement (184R) protocol active yet even 
though GOG 184 was closed to patient entry in 2004. The 
endpoint for GOG184 was Recurrence Free Survival (RFS), 
but if the endpoint of survival had been used, GOG184 would 
not be closed for analysis yet. The population of patients did 
have a high survival of 62 and 64% for each arm which delayed 
the initiation of the statistical analysis for three years from the 
date of last patient entry. The Stage IV patients (66 patients) 
were barred from further entry once GOG122 was analyzed to 
reveal that chemotherapy was superior to radiation in 
advanced endometrial carcinoma. No prospective rando-
mized trial is perfect but several questions arise when it takes 
so long to answer clinical questions. 
  During the four years of patient accrual in GOG184, 659 
patients with 2 cm or less of residual endometrial carcinoma 
following TAH/BSO with or without node dissection received 
volume directed (to site of the tumor) radiation, then 552 
were randomized to doxorubicin and cisplatin with or 
without paclitaxel. At the conclusion of the study, there was 
no difference in Recurrence Free Survival (RFS) with 62 and 
64% survival for each arm.
FUTURE CHALLENGES
  1. Should there be statistical carve outs of subgroups of the 
GOG184 552 eligible patients to develop the replacements of 
GOG184 or GOG184R's? The new GOG184R's would be 
modeled on the prior study with the primary objectives being 
to achieve results in 2-3 years rather than one result in 10 
years. For example, should a GOG184R contain any low risk 
patients that were clearly identified in GOG184 such as most 
grade 1 and 2 patients who had survivals in the 90% and 70% 
range, respectively (Fig. 1)?1 Should successive randomized 
phase II trials be designed and activated before the final 
results of the first trial are known?
  2. Should statistical carve outs of GOG184 lead to Stage III 
high risk designed protocols where only grade 3, clear cell and 
papillary serous, gross residual disease patients, and patients 
with positive para-aortic nodes are included with a projected 
30-60% survival range? Should high risk patients within 
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Fig. 1. GOG 184: Recurrence-free survival by tumor histology and grade. Fig. 2. GOG 184: Recurrence-free survival by residual tumor status. 
CD: cisplatin+doxorubicin, CDP: cisplatindoxorubicinpaclitax-
el, GRD: gross residual disease.
advanced endometrial cancer patients not be the target for 
separate protocol development? The patients at high risk in 
GOG 184 included 55% (309/552) of patients in which 41% 
had anaplastic or grade 3 with a RFS Hazard Ratio (HR) of 
3.12, 13% had serous histology with a RFS HR of 4.43, and 2% 
had clear cell (2%) histology with a RFS HR of 3.45 (Fig. 1).
  3. Should patients with gross disease be given the three drug 
combination although overall the survival between the two 
arms was similar? There is high likelihood although the 
numbers are small that the addition of paclitaxel increased 
survival for patients with gross residual disease in GOG184 
(Fig. 2).1 Yet, should gross disease patients even be included 
in GOG184R?
  4. Should full dose chemotherapy beginning with cycle one 
be administered with filgrastim or pegfilgrastim in all 
protocols as was done in GOG184, as the use of growth factor 
would likely be necessary to assure equidosing of chemo-
therapeutic agents? By making growth factor use mandatory 
in both arms of GOG184, there was no question that all 
patients received maximum dosing and afforded the use of full 
dose paclitaxel (160 mg/m2) which clearly had no influence 
on overall outcome.
  5. Should dose reduction of chemotherapeutic agents be 
based primarily on grade 1-3 neutrophil toxicity? Clinically 
inconsequential grade 3 neutrophil toxicity prompting auto-
matic dose reductions was first noted early in GOG184 when 
the protocol was amended to include growth factor manda-
torily in both arms.
  6. Should extensive pelvic node dissections, as done 
electively in GOG184, be done since, in the 552 randomized 
patients, pelvic node status was not significant? Aortic node 
status was predictive of outcome but not pelvic node status. 
Rather than recommending "node dissection," should only 
para-aortic node sampling be encouraged or should extensive 
imaging of the para-aortic nodes be used to direct extended 
field radiation if node positive?
  7. How should radiation and chemotherapy be sequenced? 
From GOG184, it was determined that older patients can 
tolerate full dose doxorubicin and cisplatin with or without 
paclitaxel after receiving volume directed radiation with one 
half receiving vaginal brachytherapy after full staging surgery. 
So, how should these modalities is used to maximize the most 
optimal outcome?
  8. Is there a role for extended field radiation or vaginal bra-
chytherapy in advanced endometrial cancer? Within GOG184, 
no patients were randomized to receive radiation volume di-
rected treatment to tumor sites and the specific details of the 
radiation within the constraints of the protocol varied at the 
election of the radiation oncologist, therefore no conclusions 
can be reached about the effectiveness of radiation. It is possi-
ble that GOG184R may offer evaluation of radiation vs che-
motherapy to finally address the need for what form of radia-
tion in advanced endometrial carcinoma is useful. 
  9. Should other treatment approaches for advanced 
endometrial carcinoma be considered such as IP therapy, 
chemoradiation, or molecular targeting agents combined with 
chemotherapy?
  10. Should clinical trials of the future for advanced endo-
metrial carcinoma be primarily based upon the statistically sig-
nificant (Hazards Regression Model) eight factors from 
GOG184? Stage (IV vs III), residual disease (gross vs micro-
scopic), extended field radiation (yes vs no), histology/grade 
(serous vs adenocarcinoma), positive para- aortic node (yes vs 
no), positive cytology (yes vs no), pelvic metastases (ser-
osa/adnexa yes or no) and age (risk increases with age) were 
significantly associated with RFS with the most high risk cate-
gories of clear cell/papillary serous histology and grade 3 
adenocarcinoma.1 Or should GOG184R be a duplicate ten year 
trial with different chemotherapy in the exact same population?
  11. Is it time for a change in the huge multi-year phase III 
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clinical trials approach for advanced endometrial carcinoma 
as the RFS has increased, and should replacement protocols 
be based on comprehensive statistical analyses and not 
primarily treatment outcome? Should those significant 
factors that clearly had impact on the outcome be the basis for 
several phase II and phase III trials?
CONCLUSION
  The GOG has come a long way in developing new strat-
egies in the management of advanced endometrial carcinoma. 
Surgery, chemotherapy and radiation have made the pri-
mary contributions to progress. Sophisticated statistical 
analyses are key to the understanding of the results and the 
basis for design of future trials. Upon reflection of all the 
findings of GOG184, the last trial completed by the Gyneco-
logic Oncology Group in advanced endometrial carcinoma, a 
number of challenges for the future are noted in the ten 
questions presented here. Basically, is it worth ten years to 
perform one trial to answer one clinical question in ad-
vanced endometrial carcinoma which can be a widely heter-
ogeneous group of patients?
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